Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01876641 · ClinicalTrials.gov registry record · Phase 1
Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib
A Phase 1 study, sponsored by Mohammed M Milhem.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01876641 is a Phase 1 study that was terminated before completion, run by Mohammed M Milhem. The registered enrollment target is 18 participants.
The verdict
NCT01876641, a Phase 1 study, was terminated before completion, sponsored by Mohammed M Milhem.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to see if the combination of Vemurafenib with Decitabine plus Cobimetinib improves the low therapy response rate in subjects with malignant melanoma.
Interventions
- DRUG Vemurafenib + Cobimetinib, Decitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2013-10 |
| Est. Completion | 2018-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01876641
The ClinicalTrials.gov registry entry for NCT01876641 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mohammed M Milhem, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vemurafenib + Cobimetinib, Decitabine is the first listed.
NCT01876641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01876641 about?
NCT01876641 is a clinical study titled "Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib". The purpose of this study is to see if the combination of Vemurafenib with Decitabine plus Cobimetinib improves the low therapy response rate in subjects with malignant melanoma.
What is the current status of trial NCT01876641?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2013-10. Estimated completion is 2018-09.
What interventions are being tested in trial NCT01876641?
The interventions under investigation include: Vemurafenib + Cobimetinib, Decitabine (DRUG).
Who is sponsoring clinical trial NCT01876641?
This trial is sponsored by Mohammed M Milhem, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.